CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.21
+0.24%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -98.8%
- EPS
- —
- Free cash flow
- -91.5%
- Operating cash flow
- -87.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +40.7%
- EPS
- -8.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +32.4%
- EBIT
- -44.6%
- Net income
- +30.8%
- EPS
- +58.6%
- Free cash flow
- -43.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026